What is TEVA's P/E ratio?

TEVA PHARMA INDUSTRIES LTD ADR (TEVA) currently trades at a P/E ratio of 32.16.

TEVA PHARMA INDUSTRIES LTD ADR reports a Return on Equity (ROE) of 9.11%.

What is TEVA's dividend yield?

TEVA PHARMA INDUSTRIES LTD ADR offers a dividend yield of 0.00%.

What is TEVA's Quality Score?

Our AI rates TEVA's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy TEVA?

Our AI Timing Score for TEVA is 64 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does TEVA belong to?

TEVA PHARMA INDUSTRIES LTD ADR is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NYSE exchange

TEVA (NYSE) Stock Analysis | TEVA PHARMA INDUSTRIES LTD ADR

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

TEVA AI Analysis Summary

Our AI summary for TEVA: TEVA PHARMA INDUSTRIES LTD ADR (NYSE), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 32.16, ROE of 9.11%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 64/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

TEVA

TEVA PHARMA INDUSTRIES LTD ADR

USD 35.01

-0.40 (-1.13%) Day Change

Watchlist Portfolio Compare Chart

32.16

P/E

1.56

D/E

9.1%

ROE

1.8%

ROA

0.00%

Div Yield

-1.37

PEG

TEVA PHARMA INDUSTRIES LTD ADR
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 35.01 Price -0.40 (-1.13%) Day Change	NEWS SCORE: 96

TEVA, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	96
Magic Formula Rank by ROA	2355
Magic Formula Rank by ROE	2355
Magic Formula Rank by ROIC	2435
Price	35.01
PBV / Sector	5.32 / 3.22
Earning Per Share	0.60

PE / Sector	32.16 / 29.79
PEG or PE/Growth / Sector	-1.37 / 0.13
Average 1M Daily Value	167.55 M GREAT
Average 1W Daily Value	273.03 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	4.08 / 15.21
NPM Average (%) / Sector	-3.52 / -10.83
NPM Change Average (%) / Sector	-32.55 / 117.42
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	1.77 / 8.15
ROA Average (%) / Sector	-1.16 / 2.87
ROA Change Average (%) / Sector	-21.13 / 112.70
ROE (%) / Sector	9.11 / -1.02
ROE Average (%) / Sector	-8.47 / 8.35
ROE Change Average (%) / Sector	6.50 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 08:00:34
Symbol	TEVA
Name	TEVA PHARMA INDUSTRIES LTD ADR
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NYSE
Listed Shares	1,164.43 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	41,232.36 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 124 Dvora HaNevi?a St., Tel Aviv-Yafo, Israel, 6944020

Phone: 972 3 914 8213

Website: https://www.tevapharm.com

Employees: 31,173

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.